Data / Form D filings / Iambic Therapeutics, Inc.
Iambic Therapeutics, Inc.: Form D filings
Iambic Therapeutics, Inc., a biotechnology company in San Diego, CA, filed 7 Form D notices with the SEC between 2023 and 2026. The latest, on September 9, 2026, reports $66 million sold of a $66.5 million offering to 16 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 5627 OBERLIN DRIVE, SUITE 120, San Diego, CA, 92121
- Phone
- (619) 330-5499
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1997038
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | New notice | $66,500,000 | $65,965,000 | $535,000 | 16 | Aug 14, 2026 | sec.gov |
| Apr 8, 2026 | New notice | $49,999,996 | $27,769,668 | $22,230,328 | 7 | Apr 1, 2026 | sec.gov |
| Nov 21, 2025 | New notice | $124,999,970 | $99,269,270 | $25,730,700 | 22 | Nov 6, 2025 | sec.gov |
| Jun 6, 2024 | Amendment | $49,999,998 | $38,383,040 | $11,616,958 | 11 | Apr 15, 2024 | sec.gov |
| May 7, 2024 | Amendment | $37,999,999 | $29,858,043 | $8,141,956 | 8 | Apr 15, 2024 | sec.gov |
| Apr 25, 2024 | New notice | $37,999,999 | $26,874,991 | $11,125,008 | 7 | Apr 15, 2024 | sec.gov |
| Oct 12, 2023 | New notice | $109,999,999 | $103,230,763 | $6,769,236 | 18 | Sep 29, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Thomas Miller | Executive Officer, Director | |
| Fred Manby | Executive Officer, Director | |
| Neil Josephson | Executive Officer | |
| Michael Secora | Executive Officer | |
| Jishnu Bhattacharjee | Director | |
| Evan Rachlin | Director | |
| R. Jacob Vogelstein | Director | |
| Mary Tagliaferri | Director | |
| William Rastetter | Director | |
| Kurt von Emster | Director | |
| Shalini Sharp | Director | |
| Pete Olson | Executive Officer | |
| Samit Hirawat | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Sep 7, 2026 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Iambic Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.